BioCryst Begins Phase 1 Trial With BCX9250, an Oral ALK-2 Inhibitor, for Treatment of Fibrodysplasia Ossificans Progressiva

Stock Information for BioCryst Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioCryst Pharmaceuticals Inc.

BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19
BioCryst to Present at 19th Annual Needham Healthcare Conference
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Appoints Anthony Doyle Chief Financial Officer
European Medicines Agency Validates Marketing Authorization Application for Oral, Once-Daily Berotralstat (BCX7353) to Prevent HAE Attacks
BEROTRALSTAT (BCX7353) SIGNIFICANTLY REDUCED USE OF ACUTE ON-DEMAND MEDICINE IN HAE PATIENTS IN APEX-2
BioCryst to Present New Data at American Academy of Allergy, Asthma & Immunology Annual Meeting
BioCryst Appoints Alan G. Levin to Board of Directors

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.